Node-Negative: Chemotherapy Benefit
Updated NCCN Guidelines® from the National Comprehensive Cancer Network® (NCCN®) underscore the unique advantage of the 21-gene (Oncotype DX) test as the only preferred multi-gene test to determine chemotherapy benefit for patients with node-negative early-stage breast cancer.
(See page BINV-6 in the Guidelines.)
Node-Positive: Inclusion in the Algorithm
Additionally, the NCCN Guidelines elevated multi-gene assays, including the 21-gene (Oncotype DX) test into the algorithm to consider for assessing prognosis and determining chemotherapy benefit for patients with micrometastases and 1–3 positive nodes.
(See page BINV-7 in the Guidelines.)